Progevita vs Lanserhof: Why WLC Withdrew This 2026 Comparison
WLC withdrew its Progevita-Lanserhof scores and recommendation because the methodology was not reproducible, source data had expired, and a claimed profile created an unresolved independence question.
Conflict disclosure and correction, August 28, 2026: Progevita is a claimed clinic profile on World Longevity Clinics. WLC has not published enough information about the relationship, data access, scoring method, or commercial arrangements to demonstrate that the previous comparison was independent. The scores, winner logic, treatment counts, price claims, and provider recommendations have been withdrawn.
Progevita and Lanserhof both market residential health or longevity programs in Europe. That shared category does not make their programs clinically equivalent, and it does not support a recommendation without current, symmetrical evidence.
This URL previously presented a detailed head-to-head comparison. WLC no longer considers that comparison reliable enough for a medical purchasing decision.
Why the comparison was withdrawn
Five gates failed during the editorial review.
- The declared Lanserhof source no longer resolved. A dead source could not verify current programs, prices, locations, or treatments.
- The scores were not reproducible. WLC had not published the input data, weights, calculation, uncertainty, or correction process behind scores such as methodology, value, innovation, and clinical substance.
- The evidence was asymmetric. Claims about Progevita and Lanserhof were not supported with equivalent, dated provider documents.
- The disclosure was too late and too vague. The article recommended Progevita to some readers before explaining that Progevita had a claimed WLC profile.
- Treatment breadth was treated as value. Lists including stem cells, exosomes, peptides, hormones, and infusions were used as positive differentiators without product-level evidence, regulatory context, or patient-specific risk.
The comparison also used ratings and broad price bands without enough documentation to establish the location, program, room, duration, taxes, medical inclusions, optional treatments, or follow-up represented by each number.
What can be said without overclaiming
Lanserhof’s current official site describes its locations, LANS Med concept, and current packages. Progevita’s official site describes programs in Spain.
Those provider pages can support what each organisation currently advertises. They cannot establish that one program produces better longevity outcomes, that every listed treatment is appropriate, or that WLC’s previous scores measured clinical quality.
The two offers should only be compared after normalising:
| Field | Evidence required from each provider |
|---|---|
| Program | Exact name, purpose, location, and dates |
| Duration | Arrival, departure, treatment days, and rest days |
| Accommodation | Room category, occupancy, meals, and taxes |
| Clinical assessment | Named tests, physician time, and interpretation |
| Interventions | Exact product or procedure, indication, regulatory status, and evidence |
| Follow-up | Responsible clinician, duration, records, referrals, and emergency pathway |
| Price | Dated itemized quote, exclusions, add-ons, cancellation, and refund terms |
Conditions for a future comparison
WLC should not restore a winner, score, or “choose this clinic if” section unless it publishes:
- the exact ownership and commercial relationship relevant to Progevita;
- a methodology with definitions, weights, input sources, and correction rules;
- a common evidence cutoff and symmetrical source set for both providers;
- current itemized prices and inclusions;
- product-level evidence and regulation for medical claims;
- an editorial review that separates provider statements from independent findings.
Until those conditions are met, readers should use the clinic evidence checklist and request comparable written quotes. The follow-up plan guide helps test whether either program provides continuing medical value after the residential stay.
Current WLC position
WLC does not currently recommend Progevita or Lanserhof over the other. The previous numerical scores and verdict should not be relied upon.
This page remains available as a correction record while WLC reviews external search and backlink data. It is still published with its original pubDate and canonical URL; the proposed temporary NOINDEX has not been applied.
This article is informational and does not provide medical advice. Verify current program terms directly and obtain independent clinical advice before purchasing an intervention.